ALZ.ST
Alzinova AB [ALZ.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ALZ.ST Stock Summary
Top 10 Correlated Stocks
ALZ.ST
In the News
ALZ.ST Financial details
Company Rating
-
Market Cap
83.72M
Income
-16.48M
Revenue
14.26M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
4
Optionable
No
Shortable
Yes
Earnings
15 May 2024
P/E
-8.06
Forward P/E
-
PEG
3.54
P/S
-
P/B
1.12
P/C
-
P/FCF
-4.31
Quick Ratio
4.74
Current Ratio
4.91
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.42
EPS next Y
-
EPS next Q
-
EPS this Y
-24.07%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-6.05%
Revenue last 5Y
-47.56%
Revenue Q/Q
-91.82%
EPS Q/Q
38.02%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-13%
ROE
-15%
ROC
-0.14%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.69-3.915
52W High
-74.3%
52W Low
-22.9%
RSI
55
Rel Volume
33.8
Avg Volume
108.65K
Volume
3.67M
Perf Week
55.76%
Perf Month
72.48%
Perf Quarter
2.8%
Perf Half Y
-3.63%
-
-
-
-
Beta
0.995
-
-
Volatility
0.27%, 0.21%
Prev Close
7.08%
Price
0.771
Change
10.14%
Company Profile
- Volume Average 108.65K
- Market Capitalization 83.72M
- Employee 4
- CEO Dr. Kristina Torfgard
- Headquarters Mölndal,SE
- IPO Date 2015-11-25
-
Website
https://www.alzinova.com 
Alzinova AB (publ), a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer's disease in Sweden. Its lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer's disease; and ALZ-201, a monoclonal antibody that is used for the treatment of toxic Aß oligomers. The company was founded in 2011 and is based in Mölndal, Sweden.
